NOTE
🌱 created from: nccn_flowchart_of_mantle_cell_lymphoma
lyma_regimen
Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma
- R-DHACis
- 1st Cycle: 184
- PD Change: 59 (toxicity)
- 4y PFS: 65%
- 4y OS: 75.9%
- PFS HR: -
- OS HR: -
- Outcome: Similar to R-DHACa
- Cytotoxicity: No difference
- R-DHACa
- 1st Cycle: 76
- PD Change: -
- 4y PFS: 65%
- 4y OS: 75.9%
- PFS HR: -
- OS HR: -
- Outcome: Similar to R-DHACis
- Cytotoxicity: No difference
- R-DHAOx
- 1st Cycle: 38
- PD Change: -
- 4y PFS: 86.5% (HR=0.44, p=0.02)
- 4y OS: 92% (HR=0.37, p=0.03)
- PFS HR: 0.44 (p=0.035)
- OS HR: 0.36 (p=0.045)
- Outcome: Better PFS/OS
- Cytotoxicity: Distinct effect